A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics
David L. Hava(Massachusetts Institute of Technology), James Roach(Pulmatrix (United States)), Lucy Connor(Wythenshawe Hospital), Steve Kramer(Pulmatrix (United States)), Litza McKenzie(Quotient Clinical (United Kingdom)), Dennis R. Henderson(Quotient Clinical (United Kingdom)), Clarie Swann(Quotient Clinical (United Kingdom)), Gary Layton(University of Geneva), Patrick W. Johnson(Mayo Clinic in Florida), Dave Singh(Manchester University NHS Foundation Trust), Katie Kane(Pulmatrix (United States)), Aidan K. Curran(Pulmatrix (United States)), Naimat Ullah Khan(Wythenshawe Hospital), Pauline Bedwell(Prime Minister's Office), Lisa Tan(Kingston University), Jason K. Perry(Pulmatrix (United States))
Cited by 35
Related Papers
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
|New England Journal of Medicine|2021|553
P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study
|The Lancet|2014|488
Early safety indicators of COVID-19 convalescent plasma in 5000 patients
|Journal of Clinical Investigation|2020|485
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
|New England Journal of Medicine|2023|452
Safety Update
|Mayo Clinic Proceedings|2020|432